Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,174 across all filing types
Latest filing 2024-08-06 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Unaudited Financial Results for the Quarter ended June 30, 2024.
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement dated August 6, 2024, from Lupin Limited addressed to stock exchanges in India, disclosing unaudited standalone and consolidated financial results for the quarter ended June 30, 2024. It references compliance with SEBI Listing Regulations, specifically Regulations 30, 33, and 47, which govern disclosure of quarterly financial results. The document includes detailed financial tables with revenue, expenses, profit before tax, tax expenses, and earnings per share for the quarter and prior periods. It also includes notes explaining significant events and accounting treatments during the quarter. Additionally, it contains a Limited Review Report from the statutory auditors, B S R & Co. LLP, confirming their review of the unaudited quarterly financial results. The presence of comprehensive financial data, auditor review, and the quarterly period clearly indicate this is an Interim / Quarterly Report. The document is not merely an announcement of a report or a certification letter but contains substantive financial data and analysis for the quarter. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2025
2024-08-06 English
Financial Result Updates
Interim / Quarterly Report Classification · 100% confidence The document is dated August 6, 2024, and contains detailed unaudited standalone and consolidated financial results for the quarter ended June 30, 2024. It includes comprehensive financial data such as revenue, expenses, profit before tax, tax expenses, net profit, earnings per share, and notes explaining significant events and accounting policies. The document also contains a Limited Review Report from the statutory auditors, B S R & Co. LLP, confirming the review of the interim financial results pursuant to Regulation 33 of SEBI Listing Regulations. The presence of detailed financial statements and auditor review for a quarter indicates this is an Interim / Quarterly Report. The document is lengthy (15,000 characters) and contains substantive financial data, not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2024-08-06 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, announcing the incorporation of a wholly owned subsidiary, Lupin Lanka (Private) Ltd, in Sri Lanka by Lupin Ltd. It provides details about the subsidiary, such as incorporation date, shareholding, business line, and investment amount. The document is an announcement of a corporate action (incorporation of a subsidiary) rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. The content fits the category of Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes through the creation of a new subsidiary and investment. The document length is about 5960 characters, sufficient for a detailed announcement but not a full report. Therefore, the appropriate classification is CAP with high confidence.
2024-08-05 English
Incorporation of Lupin Lanka (Private) Ltd., Sri Lanka, as wholly owned subsidiary of the Company.
Capital/Financing Update Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, announcing the incorporation of a wholly owned subsidiary, Lupin Lanka (Private) Ltd, in Sri Lanka. It provides details about the subsidiary, such as incorporation date, shareholding, business line, and investment amount. There are no financial statements or detailed financial performance data. The document is an announcement of a corporate action related to capital structure (incorporation of a subsidiary with initial investment). This fits the category of Capital/Financing Update (CAP). The document length is about 5958 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the correct classification is CAP with high confidence.
2024-08-05 English
Updates
Regulatory Filings Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about the receipt of 21 Show Cause Notices from a regulatory authority (DGGI GST Authority) regarding reversal of Input Tax Credit along with interest and penalty. The document includes details of the notices, the nature of the alleged violation, and the company's response. It is a regulatory announcement about legal and compliance matters, not a full report or financial statement. The document length is 4408 characters, which is relatively short and focused on a specific regulatory disclosure. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-08-05 English
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Regulatory Filings Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (BSE and NSE) pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It informs about the receipt of 21 Show Cause Notices from a government authority (DGGI GST Authority) regarding reversal of Input Tax Credit along with interest and penalty. The document includes details of the notices, the nature of the alleged violation, and the company's stance on the matter. There are no financial statements, earnings data, or detailed management analysis. The document is a regulatory announcement about a legal/tax proceeding, not a full report or financial filing. It is a regulatory compliance disclosure about legal proceedings and is best classified as a Regulatory Filings (RNS) type, which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-08-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.